^
    Back
    Association details:
    Biomarker:BCL2 overexpression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    EHA 2020
    Title:

    BIOMARKER IDENTIFICATION IN RELAPSED/REFRACTORY NON-GERMINAL CENTER B-CELL–LIKE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ZANUBRUTINIB

    Published date:
    06/27/2020
    Excerpt:
    For the 56 non-GCB patients with HTG gene expression profiles, PAX5 expression was significantly higher in monotherapy responders, and PIM1, BCL2, and FOXP1 expression was higher in combination therapy responders.
    Secondary therapy:
    CD20 inhibitor